FDA Breakthrough Therapy Designation Granted For Promising Rectal Cancer Drug
The FDA granted Breakthrough Therapy designation to dostarlimab (Jemperli), showing a 100% clinical response rate for locally advanced dMMR/MSI-H rectal cancer. Jemperli, a PD-1-blocking monoclonal antibody, offers an immunotherapy option without chemotherapy, radiation, or surgery, with ongoing trials supporting its potential.
Highlighted Terms
Related News
FDA Breakthrough Therapy Designation Granted For Promising Rectal Cancer Drug
The FDA granted Breakthrough Therapy designation to dostarlimab (Jemperli), showing a 100% clinical response rate for locally advanced dMMR/MSI-H rectal cancer. Jemperli, a PD-1-blocking monoclonal antibody, offers an immunotherapy option without chemotherapy, radiation, or surgery, with ongoing trials supporting its potential.